CA3091792A1 - Methods of use for trisubstituted benzotriazole derivatives - Google Patents
Methods of use for trisubstituted benzotriazole derivatives Download PDFInfo
- Publication number
- CA3091792A1 CA3091792A1 CA3091792A CA3091792A CA3091792A1 CA 3091792 A1 CA3091792 A1 CA 3091792A1 CA 3091792 A CA3091792 A CA 3091792A CA 3091792 A CA3091792 A CA 3091792A CA 3091792 A1 CA3091792 A1 CA 3091792A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- cell lymphoma
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2018018679 | 2018-02-20 | ||
| USPCT/US2018/018679 | 2018-02-20 | ||
| PCT/US2019/018472 WO2019164794A1 (en) | 2018-02-20 | 2019-02-19 | Methods of use for trisubstituted benzotriazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3091792A1 true CA3091792A1 (en) | 2019-08-29 |
Family
ID=61692059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3091792A Pending CA3091792A1 (en) | 2018-02-20 | 2019-02-19 | Methods of use for trisubstituted benzotriazole derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11717512B2 (https=) |
| EP (1) | EP3755324B1 (https=) |
| JP (2) | JP7434185B2 (https=) |
| KR (1) | KR102861339B1 (https=) |
| CN (1) | CN111757731B (https=) |
| AU (1) | AU2019223906B2 (https=) |
| BR (1) | BR112020016929A8 (https=) |
| CA (1) | CA3091792A1 (https=) |
| ES (1) | ES3038736T3 (https=) |
| MA (1) | MA51897A (https=) |
| MX (1) | MX2020008678A (https=) |
| TW (1) | TWI818954B (https=) |
| WO (1) | WO2019164794A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| JOP20210147A1 (ar) | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
| CN111662872A (zh) * | 2020-05-06 | 2020-09-15 | 西南医科大学附属医院 | 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法 |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| ES3063941T3 (en) * | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9708620A (es) | 1995-05-10 | 1998-02-28 | Pfizer | Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide. |
| WO2001024785A2 (en) | 1999-10-01 | 2001-04-12 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7652051B2 (en) * | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| ATE474833T1 (de) * | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| DE102005049953A1 (de) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| WO2008028860A1 (en) | 2006-09-08 | 2008-03-13 | F. Hoffmann-La Roche Ag | Benzotriazole kinase modulators |
| WO2010081898A1 (en) | 2009-01-19 | 2010-07-22 | Neurosearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US9316632B2 (en) | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| MY159575A (en) | 2009-04-02 | 2017-01-13 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| WO2013049112A1 (en) | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| CN103965133B (zh) | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| RS57962B1 (sr) * | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US11730716B2 (en) | 2014-05-08 | 2023-08-22 | Kiora Pharmaceuticals Gmbh | Compounds for treating ophthalmic diseases and disorders |
| US11096934B2 (en) | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
| JP6961879B2 (ja) | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| US11311548B2 (en) | 2017-03-02 | 2022-04-26 | Aslan Pharmaceuticals Pte. Ltd. | Cancer therapy |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| WO2020109625A1 (en) | 2018-11-30 | 2020-06-04 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
| JOP20210147A1 (ar) | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
| US12582667B2 (en) | 2019-09-27 | 2026-03-24 | The Rockefeller University | Compositions and methods to treat metastatic gastrointestinal cancer |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| ES3063941T3 (en) | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
-
2019
- 2019-02-19 TW TW108105398A patent/TWI818954B/zh active
- 2019-02-19 CA CA3091792A patent/CA3091792A1/en active Pending
- 2019-02-19 AU AU2019223906A patent/AU2019223906B2/en active Active
- 2019-02-19 CN CN201980014469.1A patent/CN111757731B/zh active Active
- 2019-02-19 MX MX2020008678A patent/MX2020008678A/es unknown
- 2019-02-19 JP JP2020566525A patent/JP7434185B2/ja active Active
- 2019-02-19 EP EP19707683.9A patent/EP3755324B1/en active Active
- 2019-02-19 MA MA051897A patent/MA51897A/fr unknown
- 2019-02-19 KR KR1020207024137A patent/KR102861339B1/ko active Active
- 2019-02-19 BR BR112020016929A patent/BR112020016929A8/pt unknown
- 2019-02-19 ES ES19707683T patent/ES3038736T3/es active Active
- 2019-02-19 WO PCT/US2019/018472 patent/WO2019164794A1/en not_active Ceased
- 2019-02-19 US US16/971,199 patent/US11717512B2/en active Active
-
2023
- 2023-05-29 JP JP2023087801A patent/JP2023109974A/ja active Pending
- 2023-06-09 US US18/207,887 patent/US12290508B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA51897A (fr) | 2020-12-30 |
| ES3038736T3 (en) | 2025-10-14 |
| BR112020016929A2 (pt) | 2020-12-15 |
| EP3755324B1 (en) | 2025-07-30 |
| JP2023109974A (ja) | 2023-08-08 |
| CN111757731B (zh) | 2024-06-25 |
| BR112020016929A8 (pt) | 2022-06-28 |
| TW201938543A (zh) | 2019-10-01 |
| KR102861339B1 (ko) | 2025-09-19 |
| EP3755324C0 (en) | 2025-07-30 |
| US12290508B2 (en) | 2025-05-06 |
| CN111757731A (zh) | 2020-10-09 |
| AU2019223906B2 (en) | 2024-11-21 |
| US20240148697A1 (en) | 2024-05-09 |
| US11717512B2 (en) | 2023-08-08 |
| JP7434185B2 (ja) | 2024-02-20 |
| WO2019164794A1 (en) | 2019-08-29 |
| EP3755324A1 (en) | 2020-12-30 |
| AU2019223906A1 (en) | 2020-09-10 |
| MX2020008678A (es) | 2020-09-25 |
| JP2021514395A (ja) | 2021-06-10 |
| US20210113531A1 (en) | 2021-04-22 |
| KR20200123137A (ko) | 2020-10-28 |
| TWI818954B (zh) | 2023-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12290508B2 (en) | Methods of use for trisubstituted benzotriazole derivatives | |
| CN104271159B (zh) | 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法 | |
| JP6855243B2 (ja) | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 | |
| US9782427B2 (en) | Methods for treating cancer using TOR kinase inhibitor combination therapy | |
| CN105050623B (zh) | Pi3k抑制剂和c-met抑制剂的组合 | |
| AU2016213972A1 (en) | Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer | |
| RU2657783C2 (ru) | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания | |
| JP2023504046A (ja) | ジアリール大環状化合物を含む併用療法 | |
| CN105338980A (zh) | 药物组合 | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| AU2014279721A1 (en) | Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent | |
| WO2018064851A1 (zh) | 低剂量西地那非作为抗肿瘤药物的应用 | |
| EP4656193A1 (en) | Pharmaceutical composition for treating tumors | |
| HK40043674B (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| HK40043674A (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| CN117794523A (zh) | 使用parp抑制剂和plk1抑制剂的癌症治疗 | |
| CN116546986A (zh) | Alk-5抑制剂及其用途 | |
| US20230090742A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors | |
| WO2025070603A1 (ja) | 血液がんの新規併用療法 | |
| HK1258689B (en) | Aminothiazole compounds and use thereof | |
| HK1258689A1 (zh) | 氨基噻唑化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250210 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250210 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250228 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250630 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251203 |